Hashizoe M, Ogura Y, Kimura H, Moritera T, Honda Y, Kyo M, Hyon S H, Ikada Y
Department of Ophthalmology, Faculty of Medicine, Kyoto University, Japan.
Arch Ophthalmol. 1994 Oct;112(10):1380-4. doi: 10.1001/archopht.1994.01090220130035.
We designed a new device, a scleral plug, that releases drugs into the vitreous after being implanted and fixed at the pars plana. Use of the plug for provision of doxorubicin hydrochloride was evaluated in rabbits. The scleral plug (8.5 mg) was made of poly(lactic-glycolic acid) (molecular weight, 40,000 daltons) containing 1% doxorubicin. Vitreous concentrations of doxorubicin were measured after the implantation. In vitro studies showed that the plug released 26% of the drug during 4 weeks. In vivo studies demonstrated that the concentration in the vitreous humor was maintained at a therapeutic range for longer than 4 weeks. No substantial toxic reactions were observed by electroretinographic and histopathologic evaluations. Our findings suggested that a scleral plug made of biodegradable polymers is a promising device for a controlled drug-release system in the vitreous.
我们设计了一种新装置——巩膜塞，它在植入并固定于睫状体扁平部后能将药物释放到玻璃体中。我们在兔子身上评估了使用该塞子提供盐酸多柔比星的情况。巩膜塞（8.5毫克）由含有1%多柔比星的聚乳酸-乙醇酸共聚物（分子量40000道尔顿）制成。植入后测量了玻璃体中多柔比星的浓度。体外研究表明，该塞子在4周内释放了26%的药物。体内研究表明，玻璃体液中的浓度在治疗范围内维持了超过4周。通过视网膜电图和组织病理学评估未观察到明显的毒性反应。我们的研究结果表明，由可生物降解聚合物制成的巩膜塞是一种用于玻璃体中药物控释系统的有前景的装置。
